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Available online 19 September 2016AbstractPurpose: To review the background, epidemiology and current management of trachoma in endemic areas and worldwide.
Methods: Review of literature.
Results: Trachoma is one of the leading causes of preventable blindness in developing countries. It was reported as one of the seven most
neglected tropical diseases that can be prevented via drug administration. Its infliction is primarily aimed at those living in areas deprived of
clean water and proper sanitation. It is estimated that trachoma is the cause of visual impairment in about 2.2 million people worldwide of which
about 1.2 million are completely blind. With implementation of the SAFE (surgery, antibiotics, facial cleanliness, and environmental control)
strategy with support from the International Trachoma Initiative (ITI) the incidence of trachoma has decreased significantly in the Middle East
and North Africa region.
Conclusion: With the enhancement of socioeconomic and sanitary status of people, advent of new generations of antibiotics, training of expert
ophthalmologists and eye care facilities the prevalence of trachoma is decreasing.
Copyright © 2016, Iranian Society of Ophthalmology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Trachoma comes from Greek word trachoma (trάcuma)
meaning “roughness”. Trachoma was well known as an in-
fectious ocular disease and documented as “ophthalmia”. The
history of this disease began as early as 8000 B.C. Taborisky
and MacCallan believe Central Asia to be the origin.1,2 Old
documents refer to Chinese therapies (2600 B.C.) and Hip-
pocratic Corpus, as well as works of several physicians;
including Celsus (1st century A.D.), Discorides (40e91 A.D.),
and Galen (129e216 A.D.). Trachoma was prevalent in
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ophthalmia” infected three thousand of Napoleon's troops in
the Egyptian war, blinding many. Napoleonic Wars accelerated
the spread of trachoma across Europe.2 In 1810, British sci-
entists proposed cleanliness, isolation, and improvement in the
living conditions of soldiers as a measure to prevent the spread
of trachoma.3 A new source of infection emerged as immi-
grants moved to the new land, America, at the end of the 19th
century. In 1897, trachoma was the first disease classified as a
dangerous contagious disease by the U.S. government. Infec-
ted immigrants were sent back to Europe by the United States
Public Health Service physicians.4
Because of the widespread distribution of trachoma, inter-
national organizations were allied to combat against this dis-
ease. Before World War II, La Ligue Contre Le Trachome and
the International Organization against Trachoma were foun-
ded. Moreover, the World Health Organization (WHO)
immediately after foundation classified trachoma as a
dangerous disease for the human beings.5sting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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chlamydia trachomatis. At first, the causing agent of trachoma
was believed to be a virus because of its small size and
inability to culture, except in living cells.6 By the 1970's,
Chlamydia trachomatis deoxyribonucleic acid (DNA) and
ribonucleic acid (RNA) were found and because of suscepti-
bility to antibiotics, it was assumed to be a bacterium.7
In the mid-20th century, the breakthrough of antimicrobials
aided the development of trachoma treatment. In the early
1950's, both topical and oral tetracyclines were investigated.
Topical tetracyclines were chosen as the most effective ther-
apy and the treatment of choice till the late twentieth century
as it had the fewest side effects. One dose of oral azithromycin
therapy in the1990's became the preferred treatment for
trachoma. With these new therapies available, trachoma
became a more preventable epidemy.8e10
In this paper, we present the background knowledge for
trachoma. To add the update, studies that were published be-
tween 2015eJune 2016 were identified. The literature search
was performed using Pubmed and Scopus databases with a
search term of “trachoma”. All original articles with English
language were selected. The literature search revealed 36 ar-
ticles. The relevant papers are discussed.
Pathogenesis
Chlamydiae are obligate intracellular bacteria. Trachoma is
caused by serotypes A, B, and C of chlamydia trachomatis.
Ocular surface chlamydia infection causes a chronic inflam-
matory reaction, which is characterized by the presence of
lymphocytic, monocytic, plasma cells and macrophages in-
filtrates. Prolonged inflammation induces conjunctival scarring
as a result of recurrent and chronic conjunctival follicular
reinfection.11,12 During a chlamydial infection the normal ar-
chitecture of the conjunctival epithelium is disrupted, the
goblet cells are lost and the normal, loose, vascular sub-
epithelial stroma is replaced with compact bands of type IV
and type V collagen.13
Trachoma is a mucopurulent keratoconjunctivitis. There is
a follicular and inflammatory response in the upper palpebral
conjunctiva. The extraocular mucous membranes like naso-
pharynx can also be infected with C. trachomatis. Typical
clinical manifestations in an endemic area seem sufficient for
the diagnosis. However, laboratory tests are needed to confirm
the diagnosis. Several different laboratory tests have shown
promise in the diagnosis of trachoma. These tests are useful
for diagnosis in areas with low prevalence or for research
purposes. Cytologic tests either by Giemsa stain14 or direct
fluorescent antibody (DFA) tests15 can detect the intra-
cytoplasmic inclusions of C. trachomatis. C. trachomatis can
also be cultured on several different cell culture systems.16
The third method called enzyme immunoassay, takes advan-
tage of binding of anti-chlamydia antibodies to certain chla-
mydial antigens.17,18 Finally, nucleic acid detection is the
newest and most sensitive test. It involves the identification of
chlamydial DNA or RNA either by probing or amplification
techniques. Nucleic acid amplification tests (NAATs) arecurrently used to assess the prevalence of trachoma infection
and thus can be used to evaluate the success of control
programs.19,20
Clinical presentation and classification
As previously noted, the physician can make the diagnosis
of trachoma on the basis of clinical manifestations in endemic
areas.
The differential diagnosis of trachoma include: allergic
conjunctivitis, viral conjunctivitis, bacterial conjunctivitis and
inclusion conjunctivitis.
Allergic conjunctivitis is the most common cause of a red
itchy eye. Scant mucosal discharge and a papillary response on
conjunctiva may also be found. Viral conjunctivitis presents
with red eye and foreign body sensation. Tender preauricular
lymph nodes may also be palpable on examination. Patients
may express a history of upper respiratory tract infection. This
is not usually present in trachoma. Bacterial conjunctivitis is
characterized by a purulent discharge. In contrast to trachoma,
follicular conjunctival reaction is rare.
Inclusion conjunctivitis or adult chlamydial conjunctivitis
is a sexually transmitted disease caused by certain serotypes of
C. trachomatis. It does not progress to trichiasis and scarring,
in contrast to trachomatous conjunctivitis.
The WHO recommends a simplified grading system for
trachoma. According to the WHO clinical disease grading of
trachoma clinical manifestations are as below.21e24
Follicular trachoma (TF) is defined by the presence of at
least 5 follicles (each at least 0.5 mm in diameter) on the
central part of the upper tarsal conjunctiva. It is believed that
the presence of follicles is an indicator of active disease. TF
is most commonly found in 3e5 year old children. Follicles
are dense collections of lymphocytes. Involution of follicles
in limbal area may result in depressions that are called
Herbert pits. These lesions are pathognomonic of past active
trachoma.
Trachomatous inflammation-intense (TI) is the pro-
nounced inflammatory thickening and papillary hypertrophy
of the upper tarsal conjunctiva obscuring more than half of the
normal deep tarsal vessels. Risk of significant conjunctival
scarring and blinding disease increases after development of
TI.
Trachomatous scarring (TS) is the presence of white
lines, bands and sheets of fibrosis in the tarsal conjunctiva. TS
is an indicator of past inflammatory disease and associated
with the development of trichiasis and dry eye syndrome.
Trichiasis (TT), the blinding lesion that opacifies the
cornea, is defined by at least one ingrowth of an eyelash touching
the eyeball or evidence of recent eyelash removal. Trichiasis
is the result of subconjunctival fibrosis over the tarsus. If TT
is corrected in a timely manner, vision can be restored.
Corneal opacity (CO) is defined by the presence of easily
visible corneal opacity over the pupil. The pupillary margin is
blurred through the opacity. CO is the blindness stage of
trachoma. Opacity includes pannus, epithelial vascularization,
and infiltration.
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The WHO advocated a strategy for the prevention and
treatment of trachoma to guide the international efforts to
eradicate this blinding disease. This public health strategy is
called “SAFE” which is a combination of the three elements of
primary, secondary and tertiary prevention. It is proved that
the SAFE strategy is highly valuable to treat and prevent
trachoma. The components of SAFE are:
 Surgery
 Antibiotics
 Facial cleanliness
 Environmental improvements
The International Trachoma Initiative (ITI) was founded in
1998 to help the achievement of the WHO's target to eliminate
blinding trachoma by 2020. ITI collaborates with govern-
mental and nongovernmental organizations at the local, na-
tional and international levels to implement SAFE strategy for
trachoma control.23e27SurgerySurgery is used to reverse the in-turned eye lashes of the
patients with trichiasis or entropion and is of paramount
importance to prevent blindness. It is a quite simple procedure
and can be readily carried out in the community or at healthcare
centers. Patients usually prefer a surgical procedure that can be
performed in an outpatient setting. Eyelash removal can relieve
the pain that is caused by rubbing the lashes over the eye but it
does not restore vision. Unfortunately this procedure has a high
recurrence rate. If TF reaches above 10%, surgery is recom-
mended when district TT prevalence exceeds 0.1%.23Antibiotic therapyThe introduction of antibiotics in the 20th century had a
revolutionary impact on trachoma control and caused the
elimination of trachoma in most developed countries by the
1950s and 1960s. The aim of antibiotic therapy is the reduc-
tion of infection burden in an affected community or treatment
of an active disease. The administration of topical tetracycline
ophthalmic ointment daily for a period of at least six weeks, or
as an alternative, annual azithromycin tablets or liquid for
infants can treat active infection.
The WHO recommends mass treatment with antibiotics in
areas where the prevalence of active trachoma exceeds 10
percent among children aged between 1 and 9 years. When the
prevalence of active disease is between 5 percent and 10
percent, either mass treatment or treatment of patients with
active disease can be chosen.24,28
Azithromycin is currently the drug of choice for treatment
of trachoma. Pfizer, the manufacturer of Azithromycin
(Zithromax®) committed to providing this drug free of charge
for trachoma control. To date, Pfizer's donation of Zithromax®
through the ITI has reached millions of people in 19 countries.As of 2015, Pfizer has donated more than 500 million
Zithromax® treatments.Facial cleanlinessThere is a strong correlation between trachoma and facial
cleanliness as children with dirty faces can both transmit the
disease if infected and catch it if not.29 Ophthalmic and nasal
discharges foster the proliferation and attraction of infective
flies, while rubbing dirty eyes with cloth, sheets and mother's
clothing, namely shawls, help transmit trachoma. Thus, it is
strongly recommended that children should have clean faces
as part of trachoma control program.26Environmental improvementIt has been long known that the prevalence of trachoma in
an area is related to the living conditions of inhabitants, access
to clean water and availability of adequate sanitation.30
Transmission of trachoma can be interrupted at the commu-
nity level by improving the living standards of inhabitants and
provision of an adequate supply of clean water.31
Any eradication program would fail without an acceptable
level of sanitation, water disposal and water quality. To have a
successful control program collaboration with other parts, such
as education, water and sanitation is mandatory. Trachoma
transmission is dependent on poor personal hygiene, fly density
and its endemicity. Therefore, the SAFE strategy addresses
poverty and development issues, aiming to improve the quality
of life for millions of people in the world's poorest countries.
Whenever TF prevalence exceeds 5% in children aged
1e9 years F and E components need to be implemented and
district-wide distribution of antibiotics should be added in any
district with a prevalence of TF higher than 10%.
All four above-mentioned components of the SAFE strat-
egy are absolutely essential in any successful control program.
Antibiotics and surgery minus hygiene and sanitation can
merely remove symptoms and not the causes of the disease.32
Improvement in domestic and personal hygiene holds great
potential for sustainable elimination of trachoma, while
treatment of active cases with antibiotics can cause the
reduction of pathogen reservoir.
Trachoma in the Middle East and North Africa
The first country that was successful in eliminating
trachoma in the Middle East and North Africa was Morocco.
This was achieved through implementation of the SAFE
strategy with support from the ITI. According to the WHO
Global Health Atlas trachoma is highly prevalent in the
Middle East and North Africa (MENA) region with more than
half a million cases of trachoma occurring in this area. Yemen
has the largest number of patients (204,000 cases), followed
by Algeria and Iraq (roughly 140,000 cases each). Despite
significant advances in the treatment of this disease in the
modern era, trachomatous trichiasis is still a public health
problem among some elderly populations in Oman,
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Iran, Morocco, and Oman have been successful in achieving
elimination goals in this area and have moved to the surveil-
lance phase.34
Unfortunately, there is no document on true prevalence of
Trachoma in Iran. However, it seems that trachoma was a
major cause of visual impairment in this country in the early
decades of the 20th century.35 After the foundation of Farabi
Eye Hospital by Professor Chams and colleagues and training
of the first generation of ophthalmologists, the prevalence of
trachoma decreased significantly.
A recent study in one of the epidemic parts of Iran, the city
of Birjnad showed that trachoma was detected in 10% of the
patients with chronic conjunctivitis. The results were similar
for both sexes. Although the findings are hospital-based, the
prevalence was not so high as to suggest prophylactic use of
azithromycin (WHO protocol) for eradication of trachoma.36
In a study in a deprived part of Iran, Sistan va Balouchestan
corneal opacities were reported to be present in 14.9% of
people with visual impairment.37 The prevalence of trachoma
in rural areas of Sistan va Balouchestan province of Iran has
been investigated in a recent study. Results of clinical eye
exams of 7912 participants were analyzed. The prevalence of
TF and TT in this population was reported to be 0.59% and
0.02%, respectively. Thus, the authors concluded that Sistan va
Balouchestan is not endemic for trachoma, despite previous
belief.38
A study on causes of visual impairment showed that un-
corrected refractive errors and cataract had a major role as
causes of visual impairment in Tehran, the capital of Iran.
Meanwhile corneal opacities due to all causes including
trachoma, herpetic keratitis, trauma and chemical burns con-
sisted of only 3.7 percent of causes of visual impairment in
this population.39
The eye bank of the Islamic Republic of Iran reported that
3.3 percent of cases with corneal transplantation in a tertiary
referral eye hospital in Iran were due to trachoma keratopathy
which once again shows the decreasing prevalence of
trachoma keratopathy.40
In conclusion, it seems that with the enhancement of so-
cioeconomic and sanitary status of people and advent of new
generations of antibiotics and training of ophthalmologists and
eye care facilities, the prevalence of trachoma is decreasing,
although not eradicated. In spite of this decrescendo pattern, it
should be noted that the potentially blinding complications of
trachoma need special and meticulous treatment plans.
Future directions
In 1998, the WHO called for an alliance for global elimi-
nation of blinding trachoma by the year 2020.41,42 As previously
noted, Iran is among the countries, along with Morocco and
Oman, that have reported the achievement of elimination goals
in the Middle East and North Africa along with Morocco and
Oman.34 However, a recent report showed that trachoma is still
an ongoing health problem in certain areas of eastern Iran43
despite many attempts to combat it. Several reasons havebeen suggested for this prevalence including interaction with
Afghan people, water shortage and dust storms in these areas. It
has been proven that trachoma is more prevalent in areas with
malnutrition, poor hygiene and low living standards. Previous
experiences have shown that trachoma cannot be successfully
controlled without improvement in the environmental indices of
living conditions, housing, diet, and sanitation. In fact, there are
few diseases that show this degree of correlation with living
conditions. Thus we believe that the solution of trachoma
elimination in these areas lies in proper government health and
welfare policies, funding from various sources and interaction
with water and sanitation sector. With continued efforts in the
more deprived parts of the country, we believe that trachoma
will be eliminated as a blinding disease by the year 2020.
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